[Molecular pharmacology of sarpogrelate].
Sarpogrelate, a 5-HT2A antagonist, is used clinically as a therapeutic agent for ischemic blood vessels. Thus, the present study was designed to evaluate the selectivity to 5-HT2 subtypes, to assess the pharmacological effect using porcine coronary arteries and to demonstrate the identification of the binding sites using molecular modeling. Sarpogrelate was higher selectivity to 5-HT2A than those of ketanserin, ritanserin or cyproheptadine and these results were supported by the computer modeling.